Given its crucial role in the competitive uptake of glutamine by tumor cells, SLC38A2 is likely an effective molecular marker for reflecting tumor malignancy, immune suppression status, and clinical outcomes (Huang et al., 2020; Tambay et al., 2024). Here, SLC38A2 is linked to neoplasm.